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Although human papillomavirus was identiﬁed as an aetiological factor in cervical cancer, the
key human gene drivers of this disease remain unknown. Here we apply an unbiased
approach integrating gene expression and chromosomal aberration data. In an independent
group of patients, we reconstruct and validate a gene regulatory meta-network, and identify
cell cycle and antiviral genes that constitute two major subnetworks upregulated in tumour
samples. These genes are located within the same regions as chromosomal ampliﬁcations,
most frequently on 3q. We propose a model in which selected chromosomal gains drive
activation of antiviral genes contributing to episomal virus elimination, which synergizes with
cell cycle dysregulation. These ﬁndings may help to explain the paradox of episomal human
papillomavirus decline in women with invasive cancer who were previously unable to clear
the virus.
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A
lthough it has been known for decades that persistent
infection with high-risk human papillomavirus (HPV) is
the major risk factor for the development of cervical
cancer1, the exact means by which the virus induces tumour
growth and the genomic changes that promote tumours have not
been completely elucidated2. On the one hand, it is known that
failure to mount an effective immune response facilitates viral
persistence and integration into a host genome leading to
genomic aberrations and a subsequent development of cervical
cancer after several decades3. Episomal virus can cause some
genomic instability during early stages of viral infection even
before integration into a host genome4,5. On the other hand, there
is evidence that the loss of episomal HPV is important in disease
progression after virus integration. For example, data from
biopsies suggest that precancerous lesions have more episomal
virus than high-grade tumours6,7, and data from cervical cell lines
show that cervical keratinocytes that lose episomal virus show
increased expression of viral oncogenes coded by the integrated
form8. This increase seems to be due to the loss of the regulatory
viral gene, E2, which is frequently disrupted on integration, and
which normally suppresses the expression of the viral oncogenes
E6 and E7 (ref. 2). The E6 and E7 transforming proteins have
multiple mechanisms to alter cell cycle control and to cause
genomic instability that lead to an increase of chromosomal
aberrations and mutations in cellular genes9. The loss of episomal
virus in the in vitro cell lines coincides with an increase of
antiviral immune response, and this has led to another model of
carcinogenesis, suggesting that an augment in antiviral activity
results in the elimination of episomal virus aiding tumour
progression8.
There are thus two main questions that are currently awaiting
answers: is there evidence of a similar antiviral immune response
in cervical tumours in vivo and, if yes, why would women that
have not been able to deal with HPV infection for a long time
suddenly acquire an antiviral response strong enough to generate
a dramatic decrease of viral load?
Here we sought to identify in unbiased way molecular mechan-
isms and key gene drivers that may be involved in the cervical
carcinogenesis using an integrative systems biology approach.
Although we did not originally aim to ask the above questions,
our results have positively answered the ﬁrst question and provided
the basis for solution of the paradox contained in the second one.
We started by generating gene expression data from 40 tumours
and 20 normal tissue samples. Combining these data with data
from four other independent studies, we revealed a robust set of
differentially expressed genes (DEGs) and used it to reconstruct a
gene coexpression network of cervical cancer. We found three
major subnetworks, one containing genes involved in the cell
cycle, another related to the antiviral activity, and a third minor
network related to epithelial cell differentiation. Integrating these
data with data on genomic (chromosomal) aberrations, we found
that the cell cycle and antiviral subnetworks were regulated by
genes located within the same regions of chromosomal ampliﬁca-
tion. We suggest that the activation of antiviral genes that occurs
late in women that have not otherwise made strong this response
is driven by selected chromosomal changes in HPV-transformed
cells. We propose a model in which frequent aberrations contain
regulatory genes that stimulate the antiviral response and the cell
cycle, and consequently promote the elimination of inhibitory
episomal virus and uncontrolled proliferation, allowing the
dysplastic cell to become a malignant tumour.
Results
Chromosomal aberrations regulating gene expression. We
performed a meta-analysis of gene expression microarray data
using our data set and four others from the literature
(Supplementary Table S1) to identify genes with altered expres-
sion in cervical tumour samples versus normal tissue. We
identiﬁed 1,268 genes with a false discovery rate (FDR) o1%,
of which 526 genes were downregulated in tumour samples
(Down-genes) and 742 genes were upregulated (Up-genes)
(Fig. 1a, Supplementary Data 1).
As the chromosomal imbalances may cause alterations in gene
expression, we questioned whether the identiﬁed DEGs were
located in the regions of frequent chromosomal gains or losses.
To identify regions of chromosomal aberrations in cervical cancer
we performed a meta-analysis of published comparative genomic
hybridization studies in this cancer (Supplementary Table S2).
We used a total of 269 cases from ten studies and determined the
frequencies of gains and losses for the whole genome (Fig. 1b).
Next, we retrieved information on chromosomal aberration fre-
quencies for 1268 DEGs according to their gene locations
(Supplementary Fig. S1a, Supplementary Data 2) and calculated
the difference between frequency of gain (FqG) and frequency of
loss (FqL) for each gene. In order to identify the cutoff values for
frequent losses and gains, we plotted the density distribution for
these differences (Supplementary Fig. S1b) and searched for local
minima on both sides of the distribution. The cutoff values were
 0.2 and 0.32 of (FqG—FqL) for frequent losses and frequent
gains, respectively (Supplementary Fig. S1b). The frequent loss
regions were located on chromosomes 2 (2q33-q37), 3 (3p12-
p26), 4 (4p12-p15.2, 4q13-q35), 11 (11q23-q25) and 13 (13q21)
and the frequent gain regions on chromosome 3 (3q13.2-q29)
(Supplementary Fig. S1c). In the loss regions there were 89 DEGs
(66 Down- and 23 Up-genes), and in the gain regions 62 DEGs
(53 Up- and 9 Down-genes) (Fig. 1c). Thus, we found a strong
association between chromosomal gains or losses and upregula-
tion or downregulation of gene expression (Po0.0001; Fisher’s
exact test), indicating that the majority of DEGs located in the
regions of frequent chromosomal aberrations are regulated by
these aberrations.
Gene network reconstruction and identiﬁcation of sub-
networks. Although we found that chromosomal aberrations
regulated the expression of about 80% of DEGs located within
these regions, those genes represented only B9% of all DEGs. It
is known, however, that DEGs are not totally independent from
each other but rather represent a regulatory network driven by
different factors, with chromosomal aberrations being one of
them. Therefore, some DEGs can be indirectly regulated by
chromosomal gains or losses, if their expression is regulated by
another gene directly affected by a chromosomal aberration. To
uncover such regulatory relationships we employed an approach
of network reconstruction that we have previously applied to
disclose gene–gene interactions in immunodeﬁciency10. We
analysed correlations between all gene pairs formed by the
DEGs and found 3,161 correlated gene pairs with FDR r0.1%.
The network was composed of 738 genes with only a few gene
pairs not connected to the main network (Fig. 2; Po10 300;
Erd+os–Re´nyi model, see Supplementary Methods). We analysed
this network to ﬁnd subnetworks, which may have speciﬁc
biological functions. We found three major subnetworks that
contained 112 genes (sub-network 1), 54 (sub-network 2) and 19
genes (sub-network 3), respectively (Fig. 2). Using functional
enrichment analysis, we identiﬁed ‘cell cycle’ (sub-network 1),
‘response to virus’ (sub-network 2, which we name ‘antiviral’
in the manuscript) and ‘epithelial cell differentiation’
(sub-network 3) as the main Gene Ontology terms
overrepresented in these subnetworks (Supplementary Table
S3). The cell cycle and antiviral subnetworks consisted mostly
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Figure 1 | Chromosomal aberrations regulating expression of genes from frequent chromosomal gain or loss. (a) Heat map of the 1,268 genes
differentially expressed between cervical tumour and normal tissue samples in the ﬁve data sets used for the meta-analysis of gene expression microarray
data. red-upregulated, green-downregulated, grey-missing value. *Current study. (b) FqG (red) or loss (FqL, green) in the genome detected in the meta-
analysis of comparative genomic hybridization studies using cervical cancer samples. (c) Distribution of the delta values (FqG—FqL) for the 1,268 genes.
Chromosomal regions with delta values 40.32 or o0.2 were considered to be the regions of frequent gains or losses, respectively. Bar graph shows
the number of upregulated (Up) or downregulated (Down) genes in each region. There is an association between gene expression and chromosomal
aberrations for the genes in the regions of frequent gains and losses (Po0.0001; Fisher’s exact test).
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of upregulated genes and the epithelial cell differentiation
subnetwork of downregulated genes.
Hierarchy in the subnetworks. To search for key regulators of the
process and to test the regulatory relationships among the genes,
we needed to establish a hierarchy within the subnetworks. It was
previously shown for different cancers that alteration in expression
of genes located within chromosomal aberration can be a critical
event driving a disease11. Furthermore, we based our analyses
on a mathematical/statistical concept that correlation is a result of
causation unless it is found by chance. The correlations, according
to ‘Reichenbach’s common cause principles’12,13, should reﬂect
regulatory relationships. Speciﬁcally, if there is a correlation
between expression of gene X and Y, then there are three
possibilities: X regulates Y, Y regulates X or there is Z that
regulates both. Thus, for the case when X correlates with Y and
there is a known cause for X (that is, chromosomal aberration) the
most likely scenario will be that X regulates Y (see Supplementary
Fig. S2).
We used two criteria for ranking genes within subnetworks for
their potential to be key regulators: ﬁrst, frequency of chromosomal
aberrations in patient population concordant with a direction of
the change in gene expression (that is, gain corresponding to
upregulation; loss to downregulation). Second criterion was the
number of connections with other genes in the network, as this
feature had been shown to be a distinctive characteristic of major
regulators14. The top-ranked genes were considered as gene-
regulators and placed on the top of the hierarchy, followed by the
genes directly linked to them (targets) and then by the genes that
did not have direct links to the regulators. We could establish these
hierarchies for subnetworks 1 (Fig. 3a) and 2 (Fig. 3b), but not for
subnetwork 3 (Supplementary Fig. S3a) as there was no gene that
met the ﬁrst criterion of a regulator in this subnetwork.
In order to test the hierarchies of the subnetworks in the
experimental settings, we took an advantage of the CMAP
database15, which contains global gene expression data of in vitro
responses to a big variety of perturbations. First, we divided
each subnetwork into two groups of genes: the ﬁrst mainly
containing regulators and the second one targets (Supplementary
Fig. S3b,c). We tested the hypothesis that perturbagens that
stimulate regulators should also stimulate targets of the given
subnetwork.
For each subnetwork we chose 20 perturbagens, which induced
regulators (that is, acting perturbagens). Next, we tested if these
perturbagens also acted on the target genes. As controls, we also
selected perturbagens, which did not act on the regulator genes
(non-acting perturbagens). As a speciﬁcity control, we tested these
perturbagens on the genes from the other subnetwork. For both
subnetworks, we observed that perturbagens selected on the basis
of their ability to stimulate regulators also stimulated targets of a
given subnetwork, but not genes of another subnetwork (Fig. 3c).
Perturbagens with no effect on regulators did not show any effect
on the targets either. Therefore, these results give us experimental
support for the two ideas emerging from network analysis: ﬁrst,
no or minimal cross-regulation between genes of different
subnetworks; and the second, that genes deﬁned as regulators
can drive the expression of target genes from the same subnetwork.
It is important, though, to interpret these results in combination
with other data because in isolation they do not rule out a
possibility that regulators and targets are under common
regulatory mechanisms affected by perturbagens.
Validation of genomic aberrations and gene expression
network. Although the meta-analyses of chromosomal aberra-
tions and gene expression network were performed using many
independent studies, we wanted to validate these results by ana-
lysing another cohort of patients. For this, we used an indepen-
dent data set containing comparative genomic hybridization
data on 97 patients with cervical cancer16 and obtained gene
expression data for 82 of them. First, we checked for the overall
concordance of the genomic aberrations of the drivers/regulators
genes between this new data set and our meta-analysis. We
observed a remarkably strong correlation between the two results
(r¼ 0.8, Po0.0001, Pearson correlation, Fig. 4a) further
supporting the idea that genomic aberrations in those genes are
a general feature of invasive cervical cancers.
Next, we wanted to ensure the reproducibility of the gene
expression meta-network. Using gene expression data of 82
tumours, we analysed connections of the meta-network in the
new data and found that B96% of the signiﬁcant correlations
(FDRo10%) had the same directions as in the original network.
Next we analysed the substructure of this network and found
three major subnetworks, which corresponded to those previously
revealed in the original meta-network (Fig. 4b). Remarkably,
each of the three subnetworks contained about 90% of
genes out of the original subnetworks and all but one of the
identiﬁed major key regulators were within the subnetworks.
After a detailed inspection, we found that the missing major
regulator gene (GMPS) actually does not have a probe on the
Illumina platform that we have used for this new experiment.
Overall, these results show that the meta-network we have
reconstructed is highly reproducible in a new set of patients,
demonstrating the robustness of our approach to meta-network
reconstruction.
As the validation patient data set had both genomic aberrations
data and gene expression data, we could directly ask whether the
chromosomal gains in the key driver genes inﬂuence their
expression. We found (as was predicted by our previous analysis,
Antiviral
Cell cycle
1
2
Epithelial
differentiation
3
Figure 2 | Gene regulatory network reconstructed using the DEGs in
cervical cancer. Dots are genes (red, upregulated; green, downregulated);
lines indicate the presence of correlation between genes. The three
identiﬁed subnetworks indicated by circles were named after Gene
Ontology terms they represent as Cell Cycle, Antiviral (equivalent to GO
term ‘response to virus’), and Epithelial differentiation.
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Fig. 1c) that expression of the key drivers was higher in tumours
that had chromosomal ampliﬁcations in regions where these
genes were located than in tumours with no aberrations or with
losses in these regions (Fig. 4c).
Next we asked whether the genes we predicted to be the targets
of the key drivers have different expression depending whether
the drivers have chromosomal gains or not. We tested this
question by comparing the expression signature of target genes
directly connected in the meta-network to the six driver genes
between tumours with and without gains for the driver genes.
To avoid biases, we only tested those target genes that were not
located on the same chromosome with their corresponding
driver. We observed that the signatures of target genes respective
to each key driver had higher expression in tumours with gains
than in tumours with no gains (loss and no aberration),
suggesting that majority of the targets are to be regulated by
their respective driver genes (Fig. 4d). These new results give an
independent experimental support for our claim that the key
driver genes we identiﬁed may drive the expression of the genes
connected to them in the network.
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Frequent aberrations contain cell cycle and antiviral drivers.
Although both the cell cycle and antiviral subnetworks were
upregulated in tumours, we observed only a few correlations
between gene expression of these two subnetworks. As regulator/
driver genes for both of these subnetworks were located in the
regions of frequent chromosomal gains, we hypothesized that
there might be relationships between the two subnetworks at the
genomic level. In this analysis, we could only include the 117
patients from the meta-analysis whose individual data on geno-
mic aberrations were available, as wells as data from 97 patients of
the validation data set16.
We asked if aberrations in the regions with the drivers of two
functional classes (antiviral and cell cycle) appear in different
samples reﬂecting the heterogeneity of cervical cancer or if these
aberrations are present in the same tumours.
In the meta-analysis and the validation data set, we found a
much higher frequency of copresence of the aberrations in
regions that contained cell cycle and antiviral drivers in the same
samples than might be expected by chance (meta-analysis data
set: Po0.0001, validation data set: Po0.002; w2-test, Fig. 5a).
In order to understand the nature of this copresence
we reconstructed a chromosomal aberration network between
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gene-regulators of the cell cycle and antiviral subnetworks. As
only the validation data set contained quantitative values of the
level of chromosomal ampliﬁcation for each gene in each patient,
we used this data set to analyse correlations between these values
and to reconstruct a network (Fig. 5b). As expected, genes located
in a physical (that is, genomic) proximity to one another showed
high correlations at the level of genomic aberrations (green edges,
Fig. 5b) despite their afﬁliations with different gene expression
subnetworks (cell cycle and antiviral). Note that genes for several
other processes are located in the same chromosomal gains as cell
cycle and antiviral gene drivers. Many of those genes were also
among differentially expressed but they were not classiﬁed as
drivers in the analysis. For example, in the frequently gained
region 3q13.2 to 3q27.3, there were 46 overexpressed genes but
only seven were identiﬁed as regulators. Thus it’s only a minority
of the genes located within frequent chromosomal aberrations
that are identiﬁed as regulators by our analysis, but all of those
represented either cell cycle or antiviral genes.
We next asked if each tumour contained aberrations from only
one chromosomal region. This was not the case. The majority of
tumours contained gains in four or more chromosomal loci with
a total of 58 unique combinations across 97 tumours (Fig. 5c;
Supplementary Fig. S4). Differently from the link between cell
cycle and antiviral drivers, we did not ﬁnd any particularly
preferred combination pair. For example, two most frequent
aberrations in 3q and 1q appear in 76% and 64% of tumours,
respectively. The proportion of tumours where these two
aberrations co-occur is B50%, which is almost the same as
would be expected by chance (48%). The analysis of more
complex combinations (three to seven aberrations) was precluded
by the available sample size.
Thus, altogether these results suggested that the combinations
of frequent chromosomal aberrations that contain cell cycle and
antiviral drivers seem to be necessary for the development of
invasive carcinoma indicating potential synergy between the two
biological processes.
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LAMP3 as a regulator of antiviral genes in cervical cancer. The
increased activity of the cell cycle genes and decreased epithelial
differentiation are well known attributes of different malig-
nancies, including cervical cancer17. The ﬁnding of increased
expression of genes related to the antiviral response was
surprising, because persistent high-risk HPV infection is highly
associated with malignancy1. Among these genes there were
innate immune sensors of viruses (ADAR, AIM2), molecules
involved in antigen presentation (HLA, TAP, RFX5),
transcription regulators (IRF1, IRF7, IRF9, and STAT1) and
other genes of innate immunity (such as HERC5, MX1, OAS2,
ISG15, and RSAD2 (viperin)) directly involved in the elimination
of viruses18,19.
In order to test whether the antiviral subnetwork genes
would be active in other infections, we compared expression of
this signature between cervical cancer and several viral and
bacterial infections. The great majority of the genes of the
antiviral subnetwork were concordantly regulated in cervical
cancer and in inﬂuenza virus, rhinovirus and respiratory
sincitial virus infections, whereas there was no similarity to
bacterial infections (Supplementary Fig. S5), indicating that
cervical cancer has gene expression properties of activated
antiviral response represented by genes of the corresponding
subnetwork.
In order to test if genes we have predicted as antiviral from
ex vivo tumour data are actually regulated in the context of a well-
deﬁned experimental HPV infection, we took advantage of the
gene expression data obtained in the in vitro W12 system of
cervical carcinogenesis8. In this model, the authors demonstrated
that outgrowth of HPV-integrated cells was associated with the
loss of episomal HPV and simultaneous activation of antiviral
response. Therefore, we tested if the genes from the antiviral
subnetwork we found in patients were associated with the loss of
episomal virus in this in vitro system. From the 54 genes of
antiviral subnetwork, 36 were detected in the vitro model, and
of those, 18 were signiﬁcantly regulated (FDRo10%), with 16 out
of 18 genes having higher expression during episomal HPV
elimination in vitro (Fig. 6a). Out of 18 genes that did not pass the
threshold, 11 also had higher expression at the stage of episomal
E2 drop. This result supports the idea that activation
of antiviral genes in vivo might be involved in the elimination
of episomal virus in tumours. Further, analysing effect of
interferon treatment we found that tumour-derived antiviral
signature contained pathways dependent on both types of
interferon (Supplementary Fig. S6).
We demonstrated that LAMP3 was one of the major regulators
of antiviral subnetwork with chromosomal ampliﬁcations of its
genomic region occurring in 450% of patients. Although this
gene is known to be regulated by interferon20 and might be
involved in antigen presentation21, its precise role in immune
response is uncertain. Therefore, we decided to further test the
role of LAMP3 as a regulator of antiviral genes. We compared the
expression signature of the genes from the antiviral subnetwork
between LAMP3 short interfering RNA (siRNA) and control
siRNA-treated HeLa cells after interferon stimulation. All 17
genes but one (IL15RA) that showed signiﬁcant difference
(FDRo10%) in gene expression between cells treated with
control- and LAMP3-siRNA were regulated as predicted by our
meta-analysis, that is had lower expression in cells where LAMP3
was knocked down (Fig. 6b). Several well-known interferon
(IFN)-dependent antiviral genes such as STAT1, IRF7, HERC5,
ISG20 and OAS1 were affected by LAMP3 downregulation. Thus,
taking together the knockdown and chromosomal ampliﬁcation
results, we conclude that LAMP3 has a key regulatory role in the
activation of interferon-dependent antiviral genes in cervical
cancer.
Discussion
As only a small percentage of women harbouring the virus
develop the cancer22, HPV infection alone appears to be
insufﬁcient for the progression of cervical cancer23. Thus, the
interaction between the infected cells, immune system and virus
seems to be involved in the malignant progression of cervical
cancer. Aiming to understand this complex process, we started by
integrating global transcriptional proﬁling and genomic data and
found that only small proportion (B9%) of DEGs can be directly
regulated by frequent chromosomal aberrations. This result led
us to hypothesize that the genes regulated by chromosomal
aberrations might themselves regulate other genes. To
substantiate this claim, we reconstructed a coexpression gene
network of cervical cancer. There were multiple pieces of evidence
indicating that this coexpression network reﬂects causative
relationships between genes. First, we found that in vitro
perturbation of major regulators of each individual subnetwork,
located within chromosomal ampliﬁcations, resulted in a similar
effect on target genes of the same sub-network, but did not affect
unrelated genes (Fig. 3c). Second, using independent cohort of
patients in whom we could obtain gene expression and genomic
aberrations data we demonstrated that genes predicted to be
targets of key drivers had higher expression in tumours with
genomic gains than in tumours without gains for respective
drivers (Fig. 4d). The last but not the least, we showed that
in vitro knockdown of LAMP3 leads to downregulation of many
antiviral genes predicted to be stimulated by this molecule by our
analysis. Altogether these ﬁndings strongly support our model
that majority of transcriptional events in cervical cancer are
directly and indirectly driven by chromosomal aberrations.
The identiﬁcation of two subnetworks, cell cycle and epithelial
cell differentiation, was not surprising, as both were extensively
studied in cervical cancer17. From the cell cycle subnetwork,
six genes (CEP70, GMPS, MCM2, NAT13, RFC4 and TOPBP1)
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located in regions of frequent chromosomal aberrations were
identiﬁed as the main drivers in this subnetwork. All these genes
are located on chromosome 3q, where a frequent DNA gain
occurs. This ampliﬁcation has been previously described in
cervical cancer24. Although some of these genes have been also
demonstrated as regulated by chromosomal gains, our study is
the ﬁrst to point to their key role in driving cell cycle
transcriptional programme in cervical cancer.
The increased expression of antiviral genes was surprising,
because one could expect a reduction in the antiviral response to
occur during persistent HPV infection as E6/E7 proteins were
shown to inhibit interferon related responses25. The natural
history of infection, however, shows that in most cases antiviral
response prevails over the inhibitory activity of HPV asB90% of
women eliminate the virus. Also, Pett et al.8 made an interesting
observation in an in vitro system that activation of antiviral
immune response genes was associated with the loss of episomal
HPV16, overexpression of E6/E7 oncogenes and outgrowth of
cervical keratinocytes containing integrated HPV. These results
led them to propose a model of cervical carcinogenesis where
elimination of episomal virus, by activated immune response, is a
critical step in tumour progression because it removes the
inhibitory component of the episomal virus (E2) and releases
oncogenes expression2. Although the new model8 insightfully
proposed the antiviral response as a critical step in tumour
progression, the trigger of this gene activation, remained a
mystery. Our results provide the ﬁrst in vivo evidence that
chromosomal ampliﬁcations in the antiviral genes selected during
cancer development trigger and sustain their activation in the
tumour possibly providing additional help for the host immune
system, which was unable to eliminate the virus alone. It is
remarkable that regions of frequent chromosomal gains
simultaneously contained drivers not only of antiviral but also
of cell cycle genes in the majority of patients (Fig. 5). This result
indicates that both processes might be necessary for tumour
survival and, as might be expected, it would be cost-effective to
select one aberration that simultaneously affects both functions
(that is, killing two birds with one stone). Activation of the two
processes may have synergistic effect on the tumour progression,
because while antiviral response ultimately would lead to the
block of cell cycle repressors (p53 and retinoblastoma) by
permitting overexpression of E6/E7, the second group of drivers
directly promotes cell cycle (Fig. 7). Although this is the most
plausible model, other interpretations may exist such as that
stimulation of immune response by ‘antiviral’ drivers might be
tumour-promoting independently on the episomal HPV decline.
One of the major drivers of the antiviral sub-network, LAMP3,
was the only driver from this subnetwork located in the same gain
region (3q) as the cell cycle drivers. An overexpression of this
gene has been associated with the enhanced metastatic potential
and poor prognosis in cervical cancer26. It was not clear, however,
which cellular process is affected and leads to cancer progression
as a result of LAMP3 elevation. Our results suggest that this gene
is one of the major drivers of immune/antiviral genes activated in
the process of cervical oncogenesis, a result that can hardly be
obtained without the comprehensive reconstruction and analysis
of a genomic/transcriptomic network. Although LAMP3 had not
been shown before as a regulator of immunity, its increased
expression was associated with better response to antiviral
treatment in patients with Hepatitis C (ref. 27). Thus, our
results in tumours (Fig. 4d) and knockdown of LAMP3 by siRNA
in cell line (Fig. 6b) is the ﬁrst direct demonstration that LAMP3
drives the IFN-dependent gene expression signature, which is
highly enriched for antiviral genes such as STAT1, IRF7, HERC5,
ISG20, OAS1 among others. Taken together with the ﬁndings that
LAMP3 is involved in the cancer metastatic process26, these
results suggest that LAMP3 may have a dual role in cervical
cancer promoting expression of antiviral genes and possibly
contributing to elimination of episomic HPV and increasing the
migratory capacity of tumour cells.
Other regulators of the antiviral subnetwork were located
outside of 3q in chromosomes 1 and 20 but it was recently
shown that those regions also have characteristic aberrations in
advanced intraepithelial lesions with a high short-term risk for
progression28. Furthermore, in vitro modulation of expression
of RFX5 (ref. 29) and AIM2 (ref. 30), located on 1q, leads to
the expected changes in expression of predicted targets
(Supplementary Fig. S7). Interestingly, of the nine genes from
the antiviral subnetwork regulated by chromosomal aberrations
and considered to be regulator genes, eight are located on these
regions (3q, 1q, 1p, 20q).
Herein we show that antiviral genes we found overexpressed in
cervical cancer are active in several viral but not bacterial
infections (Supplementary Fig. S5), suggesting that host uses
common mechanism for elimination of different viruses includ-
ing HPV. These genes contain a mixed pattern of IFN type I and
type II pathways, while the in vitro results of Pett et al.8 indicated
an involvement of only type I interferon. This partial discrepancy
can probably be explained by the mixture of different cell types,
including immune cells, that generates antiviral signature in vivo.
This hypothesis is supported by the fact that expression of some
genes from antiviral subnetwork is known to be limited to
immune cells (for example, CD163, FCGR1B and granzyme B;
Supplementary Fig. S8). In addition, it agrees with the data
showing that high expression of granzyme B is associated with
poor outcome of cervical cancer patients31.
In contrast to the cell cycle and antiviral subnetworks, we did
not ﬁnd any evidence that protein coding genes located within
chromosomal aberrations can be regulators of the epithelial
differentiation subnetwork. Our bioinformatics analysis
(Supplementary Methods; Supplementary Fig. S9), however,
indicated that the genes from this subnetwork might be
downregulated by mir-15b and mir-16-2 that are located within
ampliﬁcation in 3q region and had been already shown
overexpressed in cervical cancer32–34.
A recent paper using a similar strategy has discovered major
drivers of a melanoma11. Thus, the successful application of this
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approach in such different malignancies as cervical cancer and
melanoma suggests its potential usefulness for the analysis of
almost any tumour, as genomic aberrations are generic features of
malignancies. Akavia et al.11 demonstrated that their algorithm
discovers critical drivers of carcinogenesis in ‘any tumour cohort
containing matched data for copy number aberrations and gene
expression’. The critical advantage of our approach is that we
have revealed key drivers of the process using non-matched
genomic and transcriptomic data sets with the only connection
between those being the fact that all data were collected from
patients with cervical cancer.
In summary, by reconstructing and analysing a gene regulatory
network of cervical cancer, we infer a model of carcinogenesis in
which genomic aberrations that promote cell cycle progression
and elimination of episomal HPV are the major drivers of the
process and orchestrate the growth advantage of the tumour cells
carrying them (Fig. 7). In addition to the novel analytical
approach and surprising biological insight, our study has
potentially important implications for future clinical practice.
For example, current World Health Organization guidelines on
HPV vaccination do not contain any speciﬁc recommendations in
regard to HPV status of the vaccine recipient35. Also, anti-HPV
therapy with immune-modulators inducing interferon pathways
has been proposed to treat HPV-infected women36. Our results,
however, suggest that antiviral therapy or anti-HPV therapeutic
vaccination might be dangerous for women whose lesions already
present signs of HPV integration. Furthermore, we compiled a
comprehensive list of genomic and transcriptomic markers that if
detected in preinvasive cancer lesions might be indicative of poor
prognosis.
Methods
Meta-analysis of gene expression data. We searched PubMed at the NCBI
database (http://www.ncbi.nlm.nih.gov/pubmed/) for studies of microarray in
cervical cancer (published until 03/2009) and selected four studies37–40 that: (i) had
publicly available microarray data, (ii) used tumour and normal clinical samples,
(iii) used oligonucleotide arrays and (iv) had sample size in each class X5
(Supplementary Table S1). The data were analysed using BRB Array-Tools
v3.6.0 beta 3 developed by Drs Richard Simon and Amy Peng Lam (http://
linus.nci.nih.gov/BRB-ArrayTools.html) using the original normalization used in
three studies37–38,40 and median normalization over entire the array for the fourth
study39. For all studies, we only considered genes found in at least 70% of arrays.
Besides publicly available data used in this study, we analysed gene expression in
samples collected from two unrelated cohorts of patients, ﬁrst one became a part of
meta-analysis and the second was used for validation. The ﬁrst data set consisted of
cervical cancer biopsies (n¼ 40) and normal adjacent tissue samples (n¼ 20)
(Gene Expression Omnibus accession code GSE26342). The second data set
consisted of cervical cancer samples from 82 patients (GSE27469). See details of
both cohorts in Supplementary Methods.
DEGs between tumour and normal samples were identiﬁed for each of the ﬁve
studies using random-variance t-test and then combined in a meta-analysis using
Fisher’s inverse w2-method41 as described in Supplementary Methods.
Meta-analysis of comparative genomic hybridization data. We selected ten
publications, which studied tumour clinical samples and provided either individual
comparative genomic hybridization data for their samples or graphical diagrams42–51.
A total of 269 cervical cancer cases were identiﬁed from the ten studies
(Supplementary Table S2). From each study, we extracted the number of cases with
chromosomal aberrations (gain and loss) in each chromosomal band to calculate the
FqG, FqL and the delta between them (FqG–FqL). We used the standard ISCN 1995
(an International System for human Cytogenetic Nomenclature 1995) resolution at
the 400-band level52. Chromosomal gains and losses in each study were deﬁned
according to the thresholds reported in the original papers.
Integration of gene expression and chromosomal aberrations. The chromo-
somal locations of the 1,268 DEGs identiﬁed in the gene expression meta-analysis
were determined using the NCBI database. When we did not ﬁnd the location, we
searched the Ensembl database. Based on the chromosomal location, the values of
the frequencies (FqG, FqL and delta FqG-FqL) were identiﬁed for each gene. We
used the delta values of all genes to construct a histogram that displayed their
distribution (Supplementary Fig. S1b). Using this distribution, we determined the
delta values, which were considered to be the cutoffs that identify regions with
frequent gain or loss. These were the values of local minima on both sides of the
distribution. We applied the Fisher’s exact test to test if the altered expression of
genes in these regions was signiﬁcantly associated with chromosomal aberrations.
A P-value o0.05 was considered signiﬁcant.
Reconstruction of the gene expression meta-network. Using gene expression
data from tumours in ﬁve data sets, we calculated correlations between gene pairs53
and reconstructed networks by performing meta-analysis of correlations using
similar approach employed for gene expression. The networks were visualized in
the Cytoscape Software 2.6.3 (ref. 54). To identify subnetworks of correlated genes,
we used MCODE v1.2 (Molecular Complex Detection) plug-in for Cytoscape55. To
establish a hierarchy within the subnetworks, we organized the genes as follows:
ﬁrst line, genes located in regions of frequent chromosomal aberrations and with 12
or more links (see Supplementary Methods for estimation of links number); second
line, genes located in regions with less frequent chromosomal aberrations (delta
values between  0.2 and  0.1 and between 0.1 and 0.32); third line, genes
directly connected with genes from the ﬁrst line; fourth line, genes connected with
genes from the second line; last line, the rest of the genes. Genes in lines 3 and
further did not have chromosomal aberrations (delta  0.1 to 0.1). See details in
Supplementary Methods.
Perturbagens analysis. We used the Connectivity Map 02 (CMAP)15 to perform
the perturbagen analysis. The genes of each subnetwork were divided into two
groups: regulators and targets (Supplementary Fig. S3). The regulator genes were
used to select the perturbagens and the target genes to test them. As controls, we
used genes from another subnetwork and we also analysed perturbagens, which did
not act on the regulator genes. In total, we selected 20 perturbagens that acted on
the regulator genes and 20 that did not do so. See details in Supplementary
Methods.
Chromosomal aberrations network. We used data from our meta-analysis
with the available individual patient results on genomic aberrations (n¼ 117) and
results from another independent data set16; ArrayExpress accession no. E-TABM-
398 for reconstruction of a chromosomal aberrations network. We reconstructed
the genomic aberrations network using the same approach employed for
reconstruction of gene expression network (details in Supplementary Methods).
LAMP3 knockdown experiment. HeLa cells obtained directly from American
Type Culture Collection were transfected with LAMP3-speciﬁc siRNA or control
siRNA (ON-TARGETplus SMARTpool), then stimulated with interferon and gene
tested for genes expression as described in Supplementary Methods.
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